These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26048545)

  • 1. [Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates].
    Moro Álvarez MJ; Neyro JL; Castañeda S
    Med Clin (Barc); 2016 Jan; 146(1):24-9. PubMed ID: 26048545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in the treatment of osteoporosis.
    Diab DL; Watts NB
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to use bisphosphonates safely and optimally.
    Jagpal A; Saag KG
    Rheumatology (Oxford); 2018 Nov; 57(11):1875-1876. PubMed ID: 29165674
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiresorptive Therapies for Osteoporosis.
    Weinerman S; Usera GL
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):555-60. PubMed ID: 26412797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
    Horning JA; Czajka J; Uhl RL
    Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
    [No Abstract]   [Full Text] [Related]  

  • 8. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
    Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
    Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture risk following intermission of osteoporosis therapy.
    Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
    Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate drug holidays: One size does not fit all.
    DiGiulio M; Loveless T; Heider G; Fagan K; Porsche B
    Nurse Pract; 2020 Mar; 45(3):50-55. PubMed ID: 32068658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.
    Brown JP; Morin S; Leslie W; Papaioannou A; Cheung AM; Davison KS; Goltzman D; Hanley DA; Hodsman A; Josse R; Jovaisas A; Juby A; Kaiser S; Karaplis A; Kendler D; Khan A; Ngui D; Olszynski W; Ste-Marie LG; Adachi J
    Can Fam Physician; 2014 Apr; 60(4):324-33. PubMed ID: 24733321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
    McClung M; Harris ST; Miller PD; Bauer DC; Davison KS; Dian L; Hanley DA; Kendler DL; Yuen CK; Lewiecki EM
    Am J Med; 2013 Jan; 126(1):13-20. PubMed ID: 23177553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
    Verron E; Bouler JM
    Drug Discov Today; 2014 Mar; 19(3):312-9. PubMed ID: 23974069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays.
    Damm DD; Jones DM
    Gen Dent; 2013 Aug; 61(5):33-8. PubMed ID: 23928436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical femur fracture during bisphosphonate drug holiday: a case series.
    Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R
    Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of bisphosphonates.
    Orozco C; Maalouf NM
    Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and risks of bisphosphonate therapy for osteoporosis.
    Khosla S; Bilezikian JP; Dempster DW; Lewiecki EM; Miller PD; Neer RM; Recker RR; Shane E; Shoback D; Potts JT
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2272-82. PubMed ID: 22523337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
    Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
    Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.